SURMOUNT-1: Tirzepatide 15 mg, the generational leap of 2022 SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024) randomized 2,539 obese adults without diabetes to tirzepatide 5, 10, or 15 mg/week or placebo over 72 weeks
Liraglutide Reduces Oxidative Stress and Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study
There was an overall improvement in the fasting lipid profile with tirzepatide across the SURPASS trials
Your doctor will gradually increase the dosage every 4 weeks until you reach the recommended maintenance dose of 2.4mg
The precision required to create a molecule that binds effectively to two distinct receptors is immense
All you have to do is receive the injections, and youre good to go